US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
pharmaphorum27d
Reata rockets on data for Nrf2 drug reacquired from AbbVie
AbbVie had been working with Reata on the Nrf2 programme since 2010 when it ... in the US after the drug failed studies in chronic kidney disease and diabetic kidney disease.